Synpromics logo

Synpromics gives researchers, developers and manufacturers unprecedented control of gene expression through proprietary technology that yields highly specific and active synthetic promoters, thus facilitating a competitive IP position for our partners.

Synpromics' designs and develops patentable synthetic promoters that are designed to regulate genes in a highly specific manner. Given that these promoters greatly improve upon the natural promoters on which the entire biotech industry currently relies, there is enormous potential for the company to drive the Biotech industry forward and transform the entire sector.

Contact Synpromics via their website

News Archive

22/06/2018   Synpromics' CEO David Venables wins Disruptor Entrepreneur Of The Year award...more
04/06/2018   Synpromics heads to Chicago for the ASGCT Annual Meeting...more
03/05/2018   Synpromics Awarded £1.9m Grant from Scottish Enterprise...more
21/04/2018   Synpromics to hold Scientific Symposium at AASGCT Meeting...more
23/02/2018   AI Could Revolutionize Gene Therapy - Synpromics features in MedicalExpo article...more
26/01/2018   Synpromics CSO published in MedNous: Is gene therapy coming of age?...more
25/01/2018   Synpromics Announces New Partnership with UCL to Develop Novel Gene Therapies...more
17/01/2018   Synpromics appoints new Vice President, Business Development...more
04/01/2018   Synpromics’ founder and CSO features in IPT magazine...more

28/11/2017   Synpromics Ltd is pleased to announce a new collaboration with UCL...more
11/10/2017   Synpromics named a "Prominent Player" in UK SynBio Sector...more
20/09/2017   Synpromics Announces New Research Partnership with Solid Biosciences...more
11/09/2017   Synpromics expands facilities to meet demand for revolutionary gene control technology...more
19/04/2017   Synpromics raises £5.2m of new investment...more
16/03/2017   Synpromics Granted Key Patent in Synthetic Promoter Development...more
04/01/2017   Synpromics announces research collaboration with GE Healthcare...more
04/01/2017   Synpromics Announces Research Collaboration with GE Healthcare...more

07/12/2016   Synpromics Announces Expansion of Research Collaboration with Adverum Biotechnologies...more
22/06/2016   Synpromics announces extension to collaboration with uniQure...more
19/04/2016   Synpromics Further Strengthens Board and Management Team...more
11/01/2016   Synpromics and Cell Therapy Catapult announce collaboration...more

09/12/2015   AGTC and Synpromics Limited Announce R&D Collaboration...more
14/08/2015   Synpromics receives £2.1m from EIS specialist Calculus Capital...more
05/03/2015   Synpromics Announces New Collaboration...more

20/08/2014   Synpromics announces new synthetic promoters for use in plants...more

03/10/2013   Dow AgroSciences and Synpromics Announce R&D Collaboration...more
01/10/2013   Synpromics joins the first UK synthetic biology trade mission...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

United Life Sciences

Accredited by


Scottish Development International

Preferred suppliers



Athena Market Access Solutions

Club Quarters Hotels

UK Forex foreign exchange transaction services

Precision for Medicine

Rhino Car Hire